Humanized anti-Tau(PS422) antibodies and methods of use

Patent metadata

Field	Value
Publication number	US-12297263-B2
Application number	US-202218091056-A
Country	US
Kind code	B2
Filing date	Dec 29, 2022
Priority date	Jun 24, 2015
Publication date	May 13, 2025
Grant date	May 13, 2025

Abstract

The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.

First claim

The invention claimed is:

1. A humanized antibody that binds to human Tau (pS422), wherein the antibody comprises in the heavy chain variable domain the HVRs of SEQ ID NOs: 08, 77 and SNI, and in the light chain variable domain the HVRs of SEQ ID NOs: 12, 14 and 79.

2. The humanized antibody according to claim 1 , comprising the heavy chain variable domain of SEQ ID NO: 76 and the light chain variable domain of SEQ ID NO: 78.

3. The humanized antibody according to claim 1 , wherein the antibody effector function is silent.

4. The humanized antibody according to claim 1 , wherein the antibody binds to human Tau (pS422), SEQ ID NO: 02, and does not bind to human Tau, SEQ ID NO: 01.

5. The humanized antibody according to claim 1 , wherein the antibody is
a) a full length antibody of the human subclass IgG1;
b) a full length antibody of the human subclass IgG4;
c) a full length antibody of the human subclass IgGI with the mutations L234A, L235A and P329G;
d) a full length antibody of the human subclass IgG4 with the mutations S228P, L23SE and P329G;
e) a full length antibody of the human subclass IgG1 with the mutations L234A, L235A and P329G in both heavy chains and the mutations T366W and S354C in one heavy chain and the mutations T366S, L368A, Y407V and Y349C in the respective other heavy chain; or
f) a full length antibody of the human subclass IgG4 with the mutations S228P, L235E and P329G in both heavy chains and the mutations T366W and S354C in one heavy chain and the mutations T366S, L368A, Y407V and Y349C in the respective other heavy chain.

6. A humanized bispecific antibody, comprising:
i) a first binding site comprising the heavy chain variable domain of SEQ ID NO: 76 and the light chain variable domain of SEQ ID NO: 78; and
ii) a second binding site selected from:
a) the heavy chain variable domain of SEQ ID NO: 82 and the light chain variable domain of SEQ ID NO: 85;
b) the heavy chain variable domain of SEQ ID NO: 83 and the light chain variable domain of SEQ ID NO: 85; or
c) the heavy chain variable domain of SEQ ID NO: 84 and the light chain variable domain of SEQ ID NO: 85.

Assignees

• Hoffmann La Roche

Inventors

• Dengl Stefan
• Emrich Thomas
• Georges Guy
• Goepfert Ulrich
• Grueninger Fiona
• Hugenmatter Adrian
• Jochner Anton
• Kettenberger Hubert
• Moelleken Joerg
• Moessner Ekkehard
• Mundigl Olaf
• Niewoehner Jens
• Schlothauer Tilman
• Molhoj Michael
• Brady Kevin

Classifications

• C07K2317/31

  multispecific · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/34

  Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title